Under the rule, the list price for drugs or biologics must be included if the price exceeds $35 for a month’s supply or the usual course of therapy. The benchmark $35 is a common patient monthly co-payment.
The rule requires the pricing information to be in text large enough for most people to read. It also allows companies to include list prices of competitor products and a statement that patients with health insurance may pay a different sum.
The rule will take effect in about 60 days. It was initially proposed as part of President Donald Trump’s “blueprint” to lower drug prices in the U.S.
Including list prices in TV ads could discourage patients from seeking medical care, the Pharmaceutical Research and Manufacturers of America said.
More articles on pharmacy:
Insys execs guilty of opioid racketeering scheme
Walgreens shaking up C-suite
Generic drugmakers could thrive in a recession, Moody’s says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.